Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Drug

Daiichi Sankyo Enlists Innovent Biologics as Exclusive China Partner for Vanflyta FLT3 Inhibitor in AML

Fineline Cube Aug 10, 2026
Company Deals

Transcenta and WuXi Biologics Forge Strategic CDMO Partnership with RMB 190 Million Manufacturing Facility Transaction

Fineline Cube Aug 7, 2026
Company Deals

Biogen Completes $1 Billion Acquisition of RayThera to Bolster Immunology Portfolio with Novel Small-Molecule Pipeline

Fineline Cube Aug 7, 2026
Company Deals

Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China

Fineline Cube Aug 6, 2026
Company Deals

AstraZeneca and CSPC Pharmaceutical Establish Joint Venture for Next-Generation Biologics Manufacturing Base in Shijiazhuang

Fineline Cube Aug 6, 2026
Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

Fineline Cube Aug 6, 2026
Company Drug

Alebund’s AP301 NDA Accepted by NMPA for Hyperphosphatemia in CKD Dialysis Patients

Fineline Cube Aug 10, 2026
Company Drug

Sino Biopharma’s benmelstobart-anlotinib Combo Wins NMPA Nod for First-Line sq-NSCLC

Fineline Cube Aug 10, 2026
Company Deals

ZBD Pharmaceutical Secures Marketing Rights for Teruisi’s CD20-Targeted ADC TRS005 in Relapsed/Refractory Non-Hodgkin Lymphoma

Fineline Cube May 26, 2026

Heilongjiang ZBD Pharmaceutical Co., Ltd. (SHA: 603567) announced a strategic agent marketing agreement with fellow...

Company Drug

Pierre Fabre Secures EU Recommendation for Braftovi Combo in First-Line BRAF V600E-Mutant Metastatic Colorectal Cancer

Fineline Cube May 26, 2026

Pierre Fabre Laboratories announced that the European Medicines Agency’s Committee for Medicinal Products for Human...

Company Drug

OTR Therapeutics Secures NMPA Approval for Phase Ib/II Trial of OTR-8100 – Best-in-Class Small Molecule Inhibitor for Malignant Tumors

Fineline Cube May 26, 2026

OTR Therapeutics announced that China’s National Medical Products Administration (NMPA) has granted approval to initiate...

Company Drug

D3 Bio Secures Breakthrough Therapy Designation for Elisrasib – Next-Generation KRAS G12C Inhibitor for First-Line NSCLC

Fineline Cube May 26, 2026

D3 Bio announced that China’s Center for Drug Evaluation (CDE) of the National Medical Products...

Company Deals

Sinocelltech Files for Hong Kong Secondary Listing to Expand Global Capital Access and Therapeutic Portfolio

Fineline Cube May 25, 2026

Sinocelltech Group Ltd (SHA: 688520) has filed its prospectus with the Hong Kong Stock Exchange,...

Company Deals Medical Device

Lifetech Scientific to Acquire Starway Medical Technology in $276 Million Deal to Expand Structural Heart Portfolio

Fineline Cube May 25, 2026

Lifetech Scientific Corporation (HKG: 1302) announced plans to acquire a 96.46% stake in fellow Chinese...

Company R&D

Biocytogen Launches RenSuper Workstation, AI-Driven Antibody Discovery Platform to Transform Therapeutic Development

Fineline Cube May 25, 2026

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SHA: 688796, HKG: 2315) announced the official launch of RenSuper...

Company Deals

Johnson & Johnson MedTech Partners with Beijing Shijitan Hospital to Establish China’s First Split-Type Surgical Robot Training Base

Fineline Cube May 25, 2026

Johnson & Johnson MedTech announced a strategic partnership with Beijing Shijitan Hospital, a Class 3A...

Company Drug

Cloudbreak Pharma Submits FDA IND for CBT-358, Novel SFA+ Technology-Based Dry Eye Treatment

Fineline Cube May 25, 2026

Cloudbreak Pharma Inc. (HKG: 2592) announced it has submitted an Investigational New Drug (IND) application...

Company Drug

Henlius Biotech’s PD-1 Inhibitor Hetronifly Receives CHMP Recommendation for Squamous NSCLC in EU

Fineline Cube May 25, 2026

Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that the European Medicines Agency’s Committee for Medicinal...

Company Drug

Boehringer Ingelheim’s Ofev Receives CHMP Endorsement for Idiopathic and Progressive Pulmonary Fibrosis

Fineline Cube May 25, 2026

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a...

Company Drug

Regeneron’s Otarmeni Gene Therapy Accepted for EMA Accelerated Review as First Potential Treatment for OTOF-Related Hearing Loss

Fineline Cube May 25, 2026

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that the European Medicines Agency (EMA) has accepted for...

Company Drug

Everest Medicines Secures South Korean Approval for Velsipity in Ulcerative Colitis Following Pfizer-Arena Legacy

Fineline Cube May 25, 2026

Everest Medicines (HKG: 1952) announced it has received marketing approval in South Korea for Velsipity...

Company Drug

Jiangsu Chia Tai Tianqing Secures NMPA Priority Review for LM-302 ADC in CLDN18.2-Positive Gastric Cancer

Fineline Cube May 25, 2026

Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Ltd (HKG:...

Company Drug

Lupin Secures NMPA Approval for Oseltamivir Phosphate in China Through Yabao Pharmaceuticals Partnership

Fineline Cube May 25, 2026

Lupin Limited (NSE: LUPIN) announced that China’s National Medical Products Administration (NMPA) has approved its...

Company Drug

Gilead Sciences Secures FDA Accelerated Approval for Hepcludex as First US Treatment for Hepatitis Delta Virus

Fineline Cube May 25, 2026

The U.S. Food and Drug Administration (FDA) granted accelerated approval to Gilead Sciences, Inc. (NASDAQ:...

Company Drug

AbbVie Secures CHMP Positive Opinion for MAVIRET in Acute Hepatitis C Treatment Across All Age Groups

Fineline Cube May 25, 2026

AbbVie Inc. (NYSE: ABBV) announced that the Committee for Medicinal Products for Human Use (CHMP)...

Company Drug

Daiichi Sankyo, AstraZeneca Secure FDA Approval for Datroway in Triple-Negative Breast Cancer After Phase III TROPION-Breast02 Success

Fineline Cube May 25, 2026

Daiichi Sankyo Company, Limited (TYO: 4568) and AstraZeneca PLC (NYSE: AZN) announced U.S. Food and...

Company Drug

Novo Nordisk Secures CHMP Positive Opinion for Wegovy 7.2 mg Single-Dose Pen and Oral Semaglutide in EU Obesity Treatment

Fineline Cube May 25, 2026

Novo Nordisk A/S (NYSE: NVO) announced that the Committee for Medicinal Products for Human Use...

Company Medical Device

Hangzhou Diagens Secures NMPA Category III Approval for AI AutoVision Chromosome Karyotyping System

Fineline Cube May 25, 2026

Hangzhou Diagens Biotechnology Co., Ltd. (HKG: 2526) announced it has received Category III medical device...

Posts pagination

1 … 34 35 36 … 705

Recent updates

  • Alebund’s AP301 NDA Accepted by NMPA for Hyperphosphatemia in CKD Dialysis Patients
  • Sino Biopharma’s benmelstobart-anlotinib Combo Wins NMPA Nod for First-Line sq-NSCLC
  • Hybio Files First tirzepatide Generic ANDA in China, Challenging Eli Lilly’s GLP-1 Dominance
  • Daiichi Sankyo Enlists Innovent Biologics as Exclusive China Partner for Vanflyta FLT3 Inhibitor in AML
  • CARsgen Therapeutics Secures NMPA Clinical Trial Approval for Allogeneic CAR-T Therapy CT1190B in Relapsed/Refractory Large B-Cell Lymphoma
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Alebund’s AP301 NDA Accepted by NMPA for Hyperphosphatemia in CKD Dialysis Patients

Company Drug

Sino Biopharma’s benmelstobart-anlotinib Combo Wins NMPA Nod for First-Line sq-NSCLC

Company Drug

Hybio Files First tirzepatide Generic ANDA in China, Challenging Eli Lilly’s GLP-1 Dominance

Company Deals Drug

Daiichi Sankyo Enlists Innovent Biologics as Exclusive China Partner for Vanflyta FLT3 Inhibitor in AML

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.